ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2020
Outbreak of KPC-2-producing
Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 46 citations in OpenAlex.
- Development of simplex and multiplex immunochromatographic assays for rapid detection of GES-, PER-, and VEB-producing gram-negative bacteria.Microbiology spectrum · 2026Article
- Significant Prevalence of Dual KPC/NDM Carbapenemase-ProducingAntibiotics (Basel, Switzerland) · 2025Article
- Breaking Through Resistance: A Comparative Review of New Beta-Lactamase Inhibitors (Avibactam, Vaborbactam, Relebactam) Against Multidrug-Resistant Superbugs.Antibiotics (Basel, Switzerland) · 2025Review
- Outbreak of High-Risk Clone ST323Antibiotics (Basel, Switzerland) · 2025Article
- Overexpression ofEmerging microbes & infections · 2024Article
- sRNA expression profile of KPC-2-producing carbapenem-resistant Klebsiella pneumoniae: Functional role of sRNA51.PLoS pathogens · 2024Article
- Rapid Detection of Ceftazidime/Avibactam Susceptibility/Resistance in Enterobacterales by Rapid CAZ/AVI NP Test.Emerging infectious diseases · 2024Article
- Neonatal Bloodstream Infection with Ceftazidime-Avibactam-ResistantAntibiotics (Basel, Switzerland) · 2023Article
- ThreeMicrobial genomics · 2023Article
- Use of Newer and Repurposed Antibiotics against Gram-Negative Bacteria in Neonates.Antibiotics (Basel, Switzerland) · 2023Review
- Genetic Characterization of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2023Article
- Resistance to ceftazidime-avibactam in a KPC-2-producing Klebsiella pneumoniae caused by the extended-spectrum beta-lactamase VEB-25.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2023Article
- Molecular mechanisms underlying bacterial resistance to ceftazidime/avibactam.WIREs mechanisms of disease · 2022Review
- Current and Potential Therapeutic Options for Infections Caused by Difficult-to-Treat and Pandrug Resistant Gram-Negative Bacteria in Critically Ill Patients.Antibiotics (Basel, Switzerland) · 2022Review
- Resistance to Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam in Gram-Negative MDR Bacilli: Molecular Mechanisms and Susceptibility Testing.Antibiotics (Basel, Switzerland) · 2022Review
- β-Lactam Antibiotics and β-Lactamase Enzymes Inhibitors, Part 2: Our Limited Resources.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Polyclonal Endemicity of Carbapenemase-ProducingAntibiotics (Basel, Switzerland) · 2022Article
- Ceftazidime-avibactam: are we safe from class A carbapenemase producers' infections?Folia microbiologica · 2021Review
- Nosocomial Pneumonia in the Era of Multidrug-Resistance: Updates in Diagnosis and Management.Microorganisms · 2021Review
- Emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in KPC-2-producing Klebsiella pneumoniae of sequence type 39 during treatment.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
From September to October 2019, seven patients colonised or infected with a ceftazidime-avibactam (CZA)-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.